Xevinapant (Debio 1143)
MS202359_0006
Phase 3 small_molecule terminated
Quick answer
Xevinapant (Debio 1143) for Squamous Cell Carcinoma of the Head and Neck is a Phase 3 program (small_molecule) at Serono Europe Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Serono Europe Limited
- Indication
- Squamous Cell Carcinoma of the Head and Neck
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated